H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus

Vaccine

Volumn 31, Issue 42, 2013, Pages 4702-4705

  Rudenko, Larisa ^a   Isakova Sivak, Irina ^a   Donina, Svetlana ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

Author keywords

Avian influenza H7N9; Hemagglutinin; Immune epitopes; Live attenuated influenza vaccine

Indexed keywords

EPITOPE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; AMINO ACID ANALYSIS; ARTICLE; AVIAN INFLUENZA VIRUS; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG SPECIFICITY; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H7N9; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROCONVERSION;

AVIAN INFLUENZA H7N9; HEMAGGLUTININ; IMMUNE EPITOPES; LIVE ATTENUATED INFLUENZA VACCINE;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CONSERVED SEQUENCE; CROSS PROTECTION; CROSS REACTIONS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HEALTHY VOLUNTEERS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N3 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED;

EID: 84884184553     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.040     Document Type: Article

References (20)

1. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, (April) 10.1056/NEJMoa1304459.
2. Uyeki T., Cox N. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med 2013, (April) 10.1056/NEJMp1304661.
3. Rudenko L.G., Slepushkin A.N., Monto A.S., Kendal A.P., Grigorieva E.P., Burtseva E.I., et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993, 168(4):881-887.
4. Rudenko L.G., Lonskaya N.I., Klimov A.I., Vasilieva R.I., Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ 1996, 74(1):77-84.
5. Rudenko L., Kiseleva I., Mironov A., Desheva J., Larionova N., Donina S., et al. Development of pandemic live attenuated influenza vaccine (LAIV) in Russia. Influenza Other Respi Viruses 2011, 5(Suppl. 1):333-337.
6. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Recombinant modified vaccinia virus ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009, 199(3):405-413.
7. Tamura S., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58(4):195-207.
8. Kim Y., Ponomarenko J., Zhu Z., Tamang D., Wang P., Greenbaum J., et al. Immune epitope database analysis resource. Nucleic Acids Res 2012, 40:W525-W530. (Web Server issue).
9. De Groot A.S., Berzofsky J.A. From genome to vaccine - new immunoinformatics tools for vaccine design. Methods 2004, 34(4):425-428.
10. Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., Nielsen M. NetMHC-3.0: accurate web accessible predictions of Human, Mouse, and Monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008, 36:W509-W512. (Web Server issue).
11. Peters B., Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005, 6:132.
12. Yewdell J.W., Del Val M. Immunodominance in TCD8+ responses to viruses: cell biology, cellular immunology, and mathematical models. Immunity 2004, 21(2):149-153.
13. Larsen J.E.P., Lund O., Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res 2006, 2:2.
14. Meijer A., Bosman A., van de Kamp E.E., Wilbrink B., van Beest Holle Mdu R., Koopmans M. Measurement of antibodies to avian influenza virus A (H7N7) in humans by hemagglutination inhibition test. J Virol Methods 2006, 132(March (1-2)):113-120.
15. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
16. Metreveli G., Zohari S., Ejdersund A., Berg M. Phylogenetic analysis of the hemagglutinin gene of low pathogenic avian influenza virus H7N7 strains in mallards in northern Europe. Avian Dis 2010, 54:453-456.
17. Kageyama T., Fujisaki S., Takashita E., Xu H., Yamada S., Uchida Y., et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China February to April 2013. Euro Surveill 2013, 18(15):pii=20453. Available online http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20453.
18. Talaat K.R., Karron R.A., Callahan K.A., Luke C.J., DiLorenzo S.C., Chen G.L., et al. A live attenuated H7N3 influenza virus vaccine is well-tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009, 27(28):3744-3753.
19. Joseph T., McAuliffe J., Lu B., Jin H., Kemble G., Subbarao K. Evaluation of replication and pathogenicity of avian influenza A H7 subtype viruses in a mouse model. J Virol 2007, 81(19):10558-10566.
20. Min J.Y., Vogel L., Matsuoka Y., Lu B., Swayne D., Jin H., et al. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 2010, 84(22):11950-11960.